Skip to main content

2025 ACRM Annual Fall Conference & EXPO Main banner

AT-A-GLANCE PDF

Neurodegenerative Disease

Design of a Phase 2, Randomized, Double-blind, Placebo-controlled Trial of BMS-986368, a Fatty Acid Amide Hydrolase/monoacylglycerol Lipase Inhibitor, for Spasticity Treatment in Multiple Sclerosis

Tuesday, October 28, 2025

12:15 PM - 12:30 PM

Location: Station 8

Presenting Author(s)

Francois Bethoux, MD

Director of Rehabilitation Services
Chairman, Department of Physical Medicine & Rehabilitation, Cleveland Clinic Neurological Institute
MC

Mary Coffey

Non-presenting Author(s)

BC

Brielle Carramusa

Clinical Scientist
Bristol Myers Squibb
WH

Walter Heine

Clinical Research Director
Bristol Myers Squibb
RM

Rosa Miceli

Director, Clinical Development
Bristol Myers Squibb
GG

Guangyi Gao

Senior Manager
Bristol Myers Squibb
RL

Richard Leigh-Pemberton

Late Stage Clinical Development
Bristol Myers Squibb

Learning Objectives:

Inform the reader of the study design of the currently enrolling phase 2 clinical trial for BMS-986368
Educate on the unique mechanism of action of BMS-986368, a dual fatty acid amide hydrolase/monoacylglycerol lipase inhibitor
Discuss the current treatment gap in patients with multiple sclerosis spasticity